4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

10 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

10 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

16 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

14 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

13 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

23 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

18 Sep 2024 13:05:00 By Nasdaq GlobeNewswire

4DMT Announces Presentations at Upcoming Retina Conferences

05 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

03 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

27 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

12 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

08 Aug 2024 13:05:01 By Nasdaq GlobeNewswire

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

05 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

17 Jul 2024 02:00:00 By Nasdaq GlobeNewswire

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

24 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

18 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

08 Jun 2024 13:30:00 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

06 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

04 Jun 2024 05:00:01 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

03 Jun 2024 05:00:00 By Nasdaq GlobeNewswire